ArticleCancer gene therapy2025

Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy.

Tengjiang Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.